X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Arsenic Trioxide
Therapeutic Area: Immunology Product Name: Arscimed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Phebra
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 30, 2021
Details:
Exclusive licensing agreement for the development of a patented formulation of oral arsenic trioxide in the treatment of autoimmune diseases. Initially the oral formulation of arsenic trioxide will target the treatment of patients with chronic graft-versus-host disease.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MaaT013
Therapeutic Area: Immunology Product Name: MaaT013
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Bpifrance
Deal Size: $29.5 million Upfront Cash: Undisclosed
Deal Type: Series B Financing December 01, 2020
Details:
The final closing of the Series B financing will support the advancement of an innovative fermentation production platform to develop and manufacture both “standard” high-richness, high-diversity fermented product MaaT013, and a pipeline of indication-specific candidates.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): MaaT013
Therapeutic Area: Immunology Product Name: MaaT013
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2020
Details:
Data from the Company’s compassionate use program with MaaT013 as a treatment in patients with intestinal acute Graft-versus-Host-Disease will be highlighted in an e-poster presentation.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
